Dermavant Presents Results of Tapinarof in Pivotal P-III PSOARING Program at the 29th EADV Virtual Congress

 Dermavant Presents Results of Tapinarof in Pivotal P-III PSOARING Program at the 29th EADV Virtual Congress

Dermavant Presents Results of Tapinarof in Pivotal P-III PSOARING Program at the 29th EADV Virtual Congress

Shots:

  • The pivotal P-III clinical program for tapinarof in adult with PsO consists of PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980) PSOARING 3 (NCT04053387), an ongoing long-term safety study. Positive results of P-III studies were reported in Aug’2020
  • Tapinarof previously met the 1EP in separate P-IIb trials for PsO & AD, both studies were published in JAAD. The company anticipates its NDA filling in 2021
  • Tapinarof (qd) is a steroid-free, cosmetically elegant, TAMA topical cream being developed for the treatment of PsO and AD. To date, 2200+ subjects have enrolled in 18 clinical trials of tapinarof

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Dermavant

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post